Starpharma Holdings Limited (AU:SPL) has released an update.
Starpharma Holdings Limited has announced the receipt of a $5.5 million R&D Tax Incentive refund, which supports their dendrimer technology development, including clinical-stage assets and marketed products. The Australian Government’s program aims to foster innovation and growth by funding companies engaged in eligible R&D activities. Starpharma’s CEO emphasized the incentive’s role in advancing medical products and the company’s strategic focus on enhancing asset value and sustainability.
For further insights into AU:SPL stock, check out TipRanks’ Stock Analysis page.
